3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
8
Other hematologic neoplasm
6
Tumor-Agnostic
4
Thoracic
3
Other solid neoplasm
3
Lymphoid
3
Genitourinary
3
Gastrointestinal
3
Myeloid
2
Head & Neck
2
Gynecologic
2
Dermatologic
2
Plasma cell
1
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Myeloproliferative Disorders
1
Interventions
fludarabine phosphate
58
Cyclophosphamide
54
Epoetin Alfa
43
Cyclosporine
42
Busulfan
42
Peripheral Blood Stem Cell Transplantation
38
Mycophenolic Acid
33
Darbepoetin alfa
33
Antilymphocyte Serum
31
Cytarabine
30
Whole-Body Irradiation
29
Filgrastim
29
Methotrexate
26
Tacrolimus
25
Radiotherapy
25
Melphalan
24
fludarabine
21
Methylprednisolone
17
Cord Blood Stem Cell Transplantation
17
Granulocyte Colony-Stimulating Factor
13
Etoposide
13
Daunorubicin
13
Rivaroxaban
12
apixaban
11
Thiotepa
11
sargramostim
10
epoetin beta
10
Dalteparin
10
eltrombopag
9
Alemtuzumab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Tablets
×
Classical hematology
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled